Frederick L. Locke, MD

Treatment Options for Mantle Cell Lymphoma (MCL)

ZUMA-2 Trial and Implications For CAR T in MCL

Role of CAR-T in MCL

Considerations for Treatment Selection in MCL 

Future Directions for CAR T in MCL 

Unmet Needs in MCL

Videos

Frederick Locke, MD, discusses treatment options for patients with mantle cell lymphoma and the use of CAR T-cell therapy in clinics. 

CAR T Therapy and Durable Responses in MCL

Frederick L. Locke, MD, medical director and research director of the Immune Cell Therapy Program and the co-program leader of the Immunology Program, vice chair of the Blood and Marrow Transplant and Cellular Immunotherapy program at Moffitt Cancer Center, discusses how chimeric antigen receptor (CAR) T-cell therapies have evolved over the last 30 years of research in the field of hematologic malignancies.

Early work with CAR T cells demonstrated their capabilities in animal models, but it wasn&rsquo;t until second-generation CAR T cells were introduced that the real benefit for patients was seen in larger, multicenter trials, such as the ZUMA-1 trial that led to the approval of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with large B-cell lymphomas, Locke said.

Frederick L. Locke, MD, discusses how chimeric antigen receptor (CAR) T-cell therapies have evolved over the last 30 years of research in the field of hematologic malignancies.

Frederick L. Locke, MD | Authors

Articles

CAR T Therapy and Durable Responses in MCL

How CAR T-Cell Therapy Has Evolved in Hematologic Malignancies